nach oben

Erschienen in:

01.07.2009 | Original Article

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

verfasst von: Joaquín Casal Rubio, S. Vázquez, F. Vázquez, M. Amenedo, J. L. Fírvida, J. R. Mel, G. Huidobro, E. Álvarez, M. Lázaro, G. Alonso, I. Fernández, As representatives of the Galician Group of Lung Cancer (GGCP in the Spanish acronym)

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC).

Methods

Chemonaive patients with measurable stage IIIB/IV NSCLC treated with gemcitabine and cisplatin (GC), or gemcitabine and docetaxel (GD), maximumsix cycles in a phase IIB trial.

Results

A total of 108 patients were randomized. Response rates (GC vs. GD, respectively): complete 3.6/2.0%, Partial 30.9/38.0%. Median Overall Survival (OS): 8.9 months in both groups (P = 0.53); and median time to progression (TTP): 6.2/5.5 months respectively (P = 0.61). Toxicities included (GC vs. GD, respectively): grade 3–4 neutropenia 49.1/41.2%; grade 3 thrombocytopenia 30.9/3.9%; grade 3 anemia 14.5/3.9%. Non-haematological toxicity was similar, except for nausea and vomiting, (16.3/2%); renal toxicity (3.7/0%) and hepatic toxicity (5.6/12.7%).

Conclusions

With a higher overall response rate and lower toxicity, GD is a good first treatment option for advanced NSCLC.

Donnadieu N, Paesmans M, Sculier JP (1991) Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease. Rev Mal Respir 8:197–204PubMed

Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Bmj 311:899–909

Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest oncology group experience. J Clin Oncol 9:1618–1626PubMed

Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353PubMedCrossRef

Pujol JL, Barlesi F, Daures JP (2006) Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 51:335–345PubMedCrossRef

Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484PubMedCrossRef

Matsui K, Hirashima T, Nitta T et al (2005) A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 35:181–187PubMedCrossRef

Pujol JL, Breton JL, Gervais R et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602–610PubMedCrossRef

Rigas JR (2001) Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan. Semin Oncol 28:15–20PubMedCrossRef

10.

Spiridonidis CH, Laufman LR, Carman L et al (2001) Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 12:89–94PubMedCrossRef

11.

Abratt RP, Bezwoda WR, Falkson G et al (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1535–1540PubMed

12.

Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744–749PubMed

13.

Anton A, Diaz-Fernandez N, Gonzalez Larriba JL et al (1998) Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 22:139–148PubMedCrossRef

14.

Cardenal F, Lopez-Cabrerizo MP, Anton A et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12–18PubMed

15.

Crino L, Scagliotti G, Marangolo M et al (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15:297–303PubMed

16.

Le Chevalier T, Scagliotti G, Natale R et al (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80PubMedCrossRef

17.

Kosmas C, Tsavaris N, Mylonakis N, Kalofonos HP (2003) An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. Crit Rev Oncol Hematol 45:265–275PubMedCrossRef

18.

Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597PubMedCrossRef

19.

Smit EF, Mattson K, von Pawel J et al (2003) ALIMTA (R) (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14:455–460PubMedCrossRef

20.

Brown ER, Shepherd FA (2005) Erlotinib in the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 5:767–775PubMedCrossRef

21.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef

22.

Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024PubMedCrossRef

23.

Fossella FV (2002) Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 3(suppl 2):S23–S28PubMedCrossRef

24.

Pocock SJ (1984) Clinical trials: a practical approach. Wiley Chichester

25.

Sekine I, Kubota K, Nishiwaki Y et al (1998) Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer. Ann Oncol 9:1079–1084PubMedCrossRef

26.

D’Addario G, Pintilie M, Leighl NB et al (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936PubMedCrossRef

27.

Georgoulias V, Scagliotti G, Miller V et al (2001) Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Semin Oncol 28:15–21PubMedCrossRef

28.

Casal J, Amenedo M, Mel JR et al (2007) Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol 60:725–732PubMedCrossRef

29.

Hirsh V, Whittom R, Desjardins P et al (2004) Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 46:113–118PubMedCrossRef

30.

Popa IE, Stewart K, Smith FP, Rizvi NA (2002) A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced non-small-cell lung carcinoma. Cancer 95:1714–1719PubMedCrossRef

31.

Skarlos DV, Dimopoulos AM, Kosmidis P et al (2003) Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer 41:107–111PubMedCrossRef

32.

Georgoulias V, Kouroussis C, Androulakis N et al (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17:914–920PubMed

Titel: A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
verfasst von: Joaquín Casal Rubio
S. Vázquez
F. Vázquez
M. Amenedo
J. L. Fírvida
J. R. Mel
G. Huidobro
E. Álvarez
M. Lázaro
G. Alonso
I. Fernández
As representatives of the Galician Group of Lung Cancer (GGCP in the Spanish acronym)
Publikationsdatum: 01.07.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0884-6

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat

In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B

Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy

Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie